LifeStance Health’s first quarter results were met with a notably negative market reaction, despite the company delivering revenue growth and a strong beat on non-GAAP profit. Management cited clinician base expansion and operational efficiencies as key drivers, with CEO David Bourdon highlighting that “our value proposition continues to resonate,” reflected in a clinician count exceeding 7,500. The company also pointed to improved margins, driven by streamlined operations and a new digital patient check-in system. However, management acknowledged ongoing challenges in clinician recruitment and retention, noting the highly competitive environment and the need to further enhance the clinician experience. The transition from a stock-based to a cash-based incentive program was framed as a direct response to clinician feedback.
Is now the time to buy LFST? Find out in our full research report (it’s free).
LifeStance Health Group (LFST) Q1 CY2025 Highlights:
- Revenue: $333 million vs analyst estimates of $333.5 million (10.8% year-on-year growth, in line)
- Adjusted EPS: $0.05 vs analyst estimates of $0.01 (significant beat)
- Adjusted EBITDA: $34.65 million vs analyst estimates of $30.19 million (10.4% margin, 14.7% beat)
- The company reconfirmed its revenue guidance for the full year of $1.42 billion at the midpoint
- EBITDA guidance for the full year is $140 million at the midpoint, in line with analyst expectations
- Operating Margin: 0.5%, up from -5.6% in the same quarter last year
- Sales Volumes rose 10.2% year on year (14.7% in the same quarter last year)
- Market Capitalization: $1.94 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions LifeStance Health Group’s Q1 Earnings Call
- Craig Hettenbach (Morgan Stanley) asked about ongoing clinician recruitment and retention challenges. CEO David Bourdon acknowledged a competitive landscape but emphasized LifeStance’s stable retention and ongoing adjustments to the clinician value proposition.
- Jamie Perse (Goldman Sachs) questioned how LifeStance would navigate a potential economic downturn. Bourdon stated the insurance-based model provides resilience, with potential for increased demand during periods of stress and migration from cash-pay alternatives.
- Ryan Daniels (William Blair) inquired about the timeline and benefits of the planned EHR system upgrade. Bourdon said it is in early discovery, with a focus on improving clinician experience and operational efficiency, but noted it is too early to estimate costs.
- Brian Tanquilut (Jefferies) asked about the impact of moving from stock-based to cash-based clinician incentives on recruitment and retention. Bourdon responded that clinicians prefer cash-based rewards tied to performance and quality, and expects this to better align with their needs.
- Richard Close (Canaccord Genuity) sought updates on specialty services rollout. Bourdon explained that expansion efforts are underway, with expectations for these offerings to grow faster than the core business and deliver higher margins.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be monitoring (1) progress in specialty services expansion and its contribution to revenue and margin mix, (2) improvements in clinician productivity and retention following changes to the incentive model, and (3) the impact of digital infrastructure enhancements, such as the patient check-in tool and EHR initiatives. Execution in these areas will be key indicators of LifeStance’s ability to deliver on its strategic priorities.
LifeStance Health Group currently trades at $5.25, down from $6.55 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
